Human RCTPubMed ID: 39287349·2025

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Messier SP, Lohmander LS, Runhaar J, et al.

Osteoarthritis and Cartilage, 2025 · n = 342

Key finding

Retatrutide 15mg improved WOMAC pain score by 48.2 vs 18.7 for placebo; 6-month knee pain reduction correlated more strongly with weight loss (r=0.72) than direct drug effect.

Summary

Phase 3 trial evaluating retatrutide versus placebo for knee osteoarthritis in obese subjects, measuring WOMAC scores, joint space narrowing, and pain reduction.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT

TRIUMPH 2: Retatrutide in Type 2 Diabetes and Obesity

Diabetes Care · 2024 · Human RCT